Combining zinc(ii), copper(ii) and silver(i) salicylates with metronidazole through via mechanochemistry and slurry, leads to the formation of the new metal complexes [Zn(Sal)2(MET)2] Form I (1a), [Zn(Sal)2(MET)2] Form II (1b), [Cu(Sal)2(MET)2(H2O)] Form I (2a), [C(Sal)2(MET)2 (H2O)] Form II (2b) and[Ag(Sal)(MET)] (3), that have been fully characterized via single crystal and powder X-ray diffraction and thermal techniques. Antimicrobial assays conducted on the thermodynamically stable forms of polymorphic zinc(ii) and copper(ii) complexes and the silver complex, have demonstrated that these complexes behave as effective agents against both Gram-positive and Gram-negative bacteria, including biofilm-forming strains, and evidence the potential application of crystal engineering strategies to modify and improve existing drugs in confronting the growing threat of antimicrobial resistance; our results are particularly promising if one considers the limited antimicrobial activity of pure metronidazole against aerobic pathogens.

Contini, L., Turner, R.J., Grepioni, F. (2025). Zinc(ii), copper(ii) and silver(i) salicylate-metronidazole complexes as novel antimicrobial agents. DALTON TRANSACTIONS, 54(31), 11925-11934 [10.1039/d5dt01086a].

Zinc(ii), copper(ii) and silver(i) salicylate-metronidazole complexes as novel antimicrobial agents

Contini L.;Turner R. J.;Grepioni F.
2025

Abstract

Combining zinc(ii), copper(ii) and silver(i) salicylates with metronidazole through via mechanochemistry and slurry, leads to the formation of the new metal complexes [Zn(Sal)2(MET)2] Form I (1a), [Zn(Sal)2(MET)2] Form II (1b), [Cu(Sal)2(MET)2(H2O)] Form I (2a), [C(Sal)2(MET)2 (H2O)] Form II (2b) and[Ag(Sal)(MET)] (3), that have been fully characterized via single crystal and powder X-ray diffraction and thermal techniques. Antimicrobial assays conducted on the thermodynamically stable forms of polymorphic zinc(ii) and copper(ii) complexes and the silver complex, have demonstrated that these complexes behave as effective agents against both Gram-positive and Gram-negative bacteria, including biofilm-forming strains, and evidence the potential application of crystal engineering strategies to modify and improve existing drugs in confronting the growing threat of antimicrobial resistance; our results are particularly promising if one considers the limited antimicrobial activity of pure metronidazole against aerobic pathogens.
2025
Contini, L., Turner, R.J., Grepioni, F. (2025). Zinc(ii), copper(ii) and silver(i) salicylate-metronidazole complexes as novel antimicrobial agents. DALTON TRANSACTIONS, 54(31), 11925-11934 [10.1039/d5dt01086a].
Contini, L.; Turner, R. J.; Grepioni, F.
File in questo prodotto:
File Dimensione Formato  
d5dt01086a.pdf

accesso aperto

Tipo: Versione (PDF) editoriale / Version Of Record
Licenza: Creative commons
Dimensione 1.5 MB
Formato Adobe PDF
1.5 MB Adobe PDF Visualizza/Apri
d5dt01086a1.pdf

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 2.28 MB
Formato Adobe PDF
2.28 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/1050277
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact